Loading organizations...
LSK Investment is a leading South Korean venture capital firm, providing long-term capital and strategic support to high-growth enterprises. It focuses on advanced technology companies in pharmaceutics, medical devices, and medical services. The firm offers tailored financial backing, management consulting, and an extensive network to foster robust development for its portfolio.
Established in 2016 by CEO Kim Myung Kee, LSK Investment was founded on the insight that emerging ventures need comprehensive, long-term backing beyond capital. Kim Myung Kee’s pedigree, including a PhD in Biological Science from KAIST and an MBA, plus professional experience at InterVest and LG Chem, informs the firm’s specialized investment approach.
The firm partners with innovative companies seeking specialized funding and guidance, and institutional investors pursuing long-term capital appreciation. LSK Investment’s vision centers on nurturing high-tech enterprises through disciplined fund management, prioritizing integrity and transparency. It aims to be a trusted partner advancing groundbreaking technologies.
LSK Investment has 1 tracked investment across 1 company. The latest tracked deal is $45.0M Series C in BIORCHESTRA in February 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 28, 2022 | BIORCHESTRA | $45.0M Series C | — | Chong KUN Dang Holdings, Chong KUN Dang Pharmaceutical, Daily Partners, E&venture Partners, GS Holdings, IMM Investment, NH Investment & Securities, Quantum Ventures Korea, SBI Investment, Smilegate Investment, Stick Investment, Widwin Investment |
